公开(公告)号：EP3250562A4

公开(公告)日：2018-07-11

申请号：EP16744240

申请日：2016-01-29

申请人： BIOMED VALLEY DISCOVERIES INC ,  VERTEX PHARMA

发明人： DECRESCENZO GARY ,  WELSCH DEAN ,  VLAHOVA PETINKA I ,  BOERRIGTER STEPHAN X M ,  ARONOV ALEXANDER ,  KESHAVARZ-SHOKRI ALI ,  SCANGAS ALEXANDER N ,  STAVROPOULOS KATHY ,  LITTLER BENJAMIN ,  KADIYALA IRINA NIKOLAEVNA ,  ALARGOVA ROSSITZA GUEORGUIEVA

IPC分类号： C07D401/04 ,  A61K31/4439 ,  A61K45/06 ,  A61P35/00

CPC分类号： C07D401/04 ,  A61K31/4439 ,  A61K45/06 ,  A61P35/00

摘要： The present invention provides crystalline forms of a compound of formula (I): Also provided are pharmaceutical compositions that include the provided crystalline forms and methods of using the provided crystalline forms and pharmaceutical compositions for the treatment of cancer.

公开(公告)号：EP1804821A4

公开(公告)日：2009-07-15

申请号：EP05808364

申请日：2005-09-30

申请人： VERTEX PHARMA

发明人： LIN CHAO ,  TAYLOR WILLIAM P

IPC分类号： A61K38/00 ,  A61K31/42 ,  A61K31/425 ,  A61K31/4965

CPC分类号： A61K45/06 ,  A61K31/42 ,  A61K31/425 ,  A61K31/497 ,  A61K31/7056 ,  A61K38/07 ,  A61K38/21 ,  A61K2300/00

公开(公告)号：EP1010009A4

公开(公告)日：2006-12-06

申请号：EP98922180

申请日：1998-05-14

申请人： VERTEX PHARMA SAN DIEGO LLC

发明人： STYLLI CHARI ,  BECKEY SAMUEL S ,  SHUMATE CHRISTOPHER BENTLEY ,  COASSIN PETER J

IPC分类号： G01N21/64 ,  A61K45/00 ,  B01J19/00 ,  B01L3/02 ,  B01L9/00 ,  C12M1/00 ,  C40B60/14 ,  G01N35/00 ,  G01N35/02 ,  G01N35/04 ,  G01N35/10 ,  G01N37/00 ,  G06F17/00

CPC分类号： B01L9/52 ,  B01J19/00 ,  B01J19/0046 ,  B01J2219/00011 ,  B01J2219/00315 ,  B01J2219/00328 ,  B01J2219/00691 ,  B01J2219/00695 ,  B01J2219/007 ,  B01J2219/00702 ,  B01J2219/00707 ,  B01L9/523 ,  B01L2300/0829 ,  B01L2300/0893 ,  C40B60/14 ,  G01N35/0099 ,  G01N35/028 ,  G01N35/1002 ,  G01N35/1074 ,  G01N2035/00326 ,  G01N2035/042 ,  G01N2035/0422 ,  G01N2035/0425 ,  Y10T436/11 ,  Y10T436/110833 ,  Y10T436/113332 ,  Y10T436/114165 ,  Y10T436/114998 ,  Y10T436/25 ,  Y10T436/2575

公开(公告)号：EP1549318A4

公开(公告)日：2006-03-08

申请号：EP03724367

申请日：2003-05-01

申请人： VERTEX PHARMA

发明人： CHEETHAM GRAHAM ,  KNEGTEL RONALD ,  SWENSON LOVORKA ,  COLL JOYCE T ,  RENWICK SUZANNE ,  WEBER PETER

IPC分类号： C12N9/12 ,  A61K31/517 ,  C07D401/14 ,  C07D403/12 ,  C07D417/12

CPC分类号： C12N9/1205 ,  C07K2299/00

摘要： The present invention provides crystalline molecules or molecular complexes which comprise binding pockets of Aurora-2 or its homologues. The invention also provides crystals comprising Aurora-2. The present invention also relates to a computer comprising a data storage medium encoded with the structural coordinates of Aurora-2 binding pockets and methods of using a computer to evaluate the ability of a compound to bind to the molecule or molecular complex. This invention also provides methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention provides methods of using the structure coordinates to screen for and design compounds, including inhibitory compounds, that bind to Aurora-2 or homologues thereof.

公开(公告)号：EP1429798A4

公开(公告)日：2005-03-09

申请号：EP02757449

申请日：2002-08-28

申请人： VERTEX PHARMA

发明人： CHATURVEDI PRAVIN ,  ETTE ENE

IPC分类号： A61K45/00 ,  A61K31/343 ,  A61K31/7052 ,  A61K38/21 ,  A61P31/14 ,  C07K17/08 ,  A61K38/00 ,  C07K17/00

CPC分类号： C07K17/08 ,  A61K38/212 ,  Y10S514/894 ,  A61K2300/00

摘要： The present invention relates to optimal compositions useful in treating HCV infections in humans. These compositions comprise alpha-interferon or a derivative thereof and an IMPDH inhibitor, wherein the IMPDH inhibitor is present in an amount such that a ration of Cavg/Cmin is between 1 to 10, wherein: Cavg is average plasma concentration produced by said IMPDH inhibitor in said human; and Cmin is estimated through concentration produced by said IMPDH inhibitor in said human. The present invention also relates to methods of producing and using the optimal compositions to treat HCV infections in humans.

公开(公告)号：EP1178797A4

公开(公告)日：2003-05-02

申请号：EP00916479

申请日：2000-03-17

申请人： VERTEX PHARMA

发明人： STAMOS DEAN ,  TRUDEAU MARTIN ,  BETHIEL SCOTT ,  BADIA MICHAEL ,  SAUNDERS JEFFREY

IPC分类号： C07D307/20 ,  A61K31/27 ,  A61K31/275 ,  A61K31/341 ,  A61K31/421 ,  A61K31/422 ,  A61K31/454 ,  A61K31/5377 ,  A61K31/541 ,  A61K45/00 ,  A61P1/18 ,  A61P9/10 ,  A61P11/06 ,  A61P19/02 ,  A61P29/00 ,  A61P31/12 ,  A61P35/00 ,  A61P37/02 ,  A61P43/00 ,  C07C275/40 ,  C07C275/42 ,  C07D263/32 ,  C07D413/12 ,  C07D417/12 ,  C07F9/653 ,  A61K31/277 ,  C07C275/34

CPC分类号： C07C275/40 ,  C07B2200/07 ,  C07C275/42 ,  C07D263/32 ,  C07F9/653

公开(公告)号：EP3294735A1

公开(公告)日：2018-03-21

申请号：EP16725672

申请日：2016-05-11

申请人： VERTEX PHARMA

发明人： FARMER LUC J ,  BOYD MICHAEL JOHN ,  SHANNON DEAN ,  WALDO MICHAEL ,  NTI ADDAE KWARNE W ,  ZHANG YUEGANG

IPC分类号： C07D471/04 ,  A61K31/506 ,  A61P31/16

CPC分类号： C07D471/04 ,  A61K31/4965 ,  A61K31/506 ,  A61K45/06 ,  C07B2200/13

摘要： include Hydrate 2 of Compound (1), Hydrate 3 of Compound (1), Form A of Compound (1), Form B of Compound (1), Form C of Compound (1), Form D of Compound (1), and amorphous Compound (1). Such polymorphic forms are useful for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.

公开(公告)号：EP3204358A4

公开(公告)日：2017-08-16

申请号：EP15849070

申请日：2015-10-07

申请人： VERTEX PHARMA

发明人： STROHMEIER MARK ,  CAESAR JR JOHN P ,  CONNELLY PATRICK RAYMOND ,  FAWAZ MAJED ,  LUSS-LUSIS EDUARD ,  MCCLAIN BRIAN R ,  MEDEK ALES ,  MIAO HAI ,  NTI-ADDAE KWAME WIREDU ,  YIN PING ,  ZHANG YUEGANG

IPC分类号： C07D215/56 ,  A61K31/4704 ,  A61P11/00

CPC分类号： C07D215/56 ,  A61K31/225 ,  A61K31/47 ,  A61K45/06 ,  C07B2200/13 ,  C07C69/18 ,  C07C69/30 ,  C07C69/34 ,  C07C69/58 ,  C07C69/587

摘要： The present disclosure relates to co-crystals comprising N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide (Compound 1) and a co-former and methods for their preparation. The present disclosure further relates to pharmaceutical compositions comprising the co-crystal forms, as well as methods of treatment therewith and kits.

摘要翻译： 本发明涉及包含N- [2,4-双（1,1-二甲基乙基）-5-羟基苯基] -1,4-二氢-4-氧代喹啉-3-甲酰胺（化合物1）和共晶 及其制备方法。 本公开还涉及包含共晶形式的药物组合物，以及用其治疗的方法和试剂盒。

公开(公告)号：EP3068392A4

公开(公告)日：2017-05-31

申请号：EP14862504

申请日：2014-10-31

申请人： VERTEX PHARMA

发明人： SWINNEY KELLY ANN ,  HURTER PATRICIA NELL ,  NADIG DAVID E ,  SMITH DAVID ,  THOMAS VANCE HAYDEN ,  WARMAN MARTIN PAUL

IPC分类号： A61K31/443 ,  A61K9/16 ,  A61K9/20 ,  A61K31/47 ,  A61K45/06

CPC分类号： A61K9/2095 ,  A61K9/146 ,  A61K9/1652 ,  A61K9/1682 ,  A61K9/1694 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2077 ,  A61K31/443 ,  A61K31/47 ,  A61K45/06 ,  A61K2300/00

公开(公告)号：EP1765283A4

公开(公告)日：2012-11-28

申请号：EP05757623

申请日：2005-06-08

申请人： VERTEX PHARMA

发明人： MURPHY MAURA ,  DINEHART KIRK ,  HURTER PATRICIA ,  CONNELLY PATRICK ,  CUI YONG ,  PANICUCCI RICCARDO N

IPC分类号： A61K9/14 ,  A61K9/10 ,  A61K31/454 ,  A61K31/497 ,  A61K45/06 ,  A61K47/38

CPC分类号： A61K38/07 ,  A61K9/145 ,  A61K9/146 ,  A61K9/1635 ,  A61K9/1652 ,  A61K31/497 ,  A61K45/06